PURPOSE: Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad preclinical antitumor activity and solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase II trial in patients with previously untreated advanced colorectal cancer was conducted. METHODS: PZA was administered at a dose of 750 mg/m2 intravenously over 3 h every 21 days to patients who received a total of 31 courses of PZA. RESULTS: In 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Toxicity to PZA consisted of myelosuppression and neurotoxicity that was treatment-limiting in several instances. CONCLUSION: PZA at this dose and schedule of administration is inactive in patients with colorectal cancer.
PURPOSE:Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad preclinical antitumor activity and solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase II trial in patients with previously untreated advanced colorectal cancer was conducted. METHODS:PZA was administered at a dose of 750 mg/m2 intravenously over 3 h every 21 days to patients who received a total of 31 courses of PZA. RESULTS: In 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Toxicity to PZA consisted of myelosuppression and neurotoxicity that was treatment-limiting in several instances. CONCLUSION:PZA at this dose and schedule of administration is inactive in patients with colorectal cancer.
Authors: Alex A Adjei; Joel M Reid; Charles Erlichman; Jeff A Sloan; Henry C Pitot; Steven R Alberts; Richard M Goldberg; Lorelei J Hanson; Stacie Ruben; Scott A Boemer; Pamela Atherton; Matthew M Ames; Scott H Kaufmann Journal: Invest New Drugs Date: 2002-08 Impact factor: 3.850
Authors: Bhuvaneswari Ramaswamy; Ewa Mrozek; John Philip Kuebler; Tanios Bekaii-Saab; Eric H Kraut Journal: Invest New Drugs Date: 2009-10-21 Impact factor: 3.850
Authors: M M Zalupski; A F Shields; P A Philip; M Kraut; P LoRusso; L K Heilbrun; V Vaitkevicius Journal: Invest New Drugs Date: 1998 Impact factor: 3.850
Authors: E Claire Dees; Eric K Rowinsky; Dennis A Noe; Seamus O'Reilly; Alex A Adjei; Kathy Elza-Brown; Ross C Donehower Journal: Invest New Drugs Date: 2003-02 Impact factor: 3.850